Esperion Therapeutics
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $69,113 | $51,632 | $73,834 | $137,735 |
Gross Profit | 43,482 | 34,346 | 58,215 | 127,660 |
EBITDA | -4,869 | -14,416 | -48,192 | 75,046 |
EBIT | -4,896 | -14,442 | -48,202 | 75,005 |
Net Income | -21,318 | -29,524 | -61,925 | 61,022 |
Net Change In Cash | 69,113 | 51,632 | 73,834 | 137,735 |
Free Cash Flow | -34,952 | -35,492 | -7,282 | 53,755 |
Cash | 144,761 | 144,717 | 189,304 | 226,609 |
Basic Shares | 191,056 | 194,930 | 188,793 | 189,641 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $332,314 | $116,334 | $75,475 | $78,447 |
Gross Profit | 332,314 | 73,067 | 48,508 | 64,230 |
EBITDA | 7,569 | -150,108 | -176,349 | -222,143 |
EBIT | 7,506 | -150,272 | -176,849 | -222,755 |
Net Income | -51,745 | -209,248 | -287,817 | -318,824 |
Net Change In Cash | 332,314 | 116,334 | 75,475 | 78,447 |
Cost of Revenue | -134,117 | -46,070 | ||
Free Cash Flow | -23,971 | -135,487 | -174,827 | -263,809 |
Cash | 144,761 | 82,248 | 124,775 | 208,892 |
Basic Shares | 187,181 | 103,106 | 66,407 | 28,902 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.10 |
2024-09-30 | -$0.15 |
2024-06-30 | -$0.33 |
2024-03-31 | $0.34 |
